Table 2.

Drugs currently being investigated for treatment of GCA

Drug name	Mechanism of action
Abatacept	Humanized fusion protein that modifies co-stimulation in antigen presentation, inhibiting T-cell activity
Anakinra	Monoclonal antibody to the IL-1β receptor
Baricitinib	Synthetic DMARD, which targets the intracellular pro-inflammatory Janus kinase (JAK) family of enzymes
Gevokizumab	Recombinant monoclonal antibody to IL-1β, a pro-inflammatory cytokine
Rituximab	Chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells